CN1313126C - Medicine composition for treating hyperlipemia and its preparing method - Google Patents
Medicine composition for treating hyperlipemia and its preparing method Download PDFInfo
- Publication number
- CN1313126C CN1313126C CNB200510007322XA CN200510007322A CN1313126C CN 1313126 C CN1313126 C CN 1313126C CN B200510007322X A CNB200510007322X A CN B200510007322XA CN 200510007322 A CN200510007322 A CN 200510007322A CN 1313126 C CN1313126 C CN 1313126C
- Authority
- CN
- China
- Prior art keywords
- rhizoma alismatis
- powder
- preparation
- salviae miltiorrhizae
- radix paeoniae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 21
- 238000000034 method Methods 0.000 title claims abstract description 18
- 229940079593 drug Drugs 0.000 title claims description 7
- 239000000203 mixture Substances 0.000 title abstract 4
- 201000005577 familial hyperlipidemia Diseases 0.000 title abstract 3
- 239000000843 powder Substances 0.000 claims abstract description 16
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 6
- 238000002360 preparation method Methods 0.000 claims description 19
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 15
- 238000005303 weighing Methods 0.000 claims description 12
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 11
- 239000012535 impurity Substances 0.000 claims description 8
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 claims description 6
- 239000012567 medical material Substances 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 150000007524 organic acids Chemical class 0.000 claims description 4
- 229930183118 Tanshinone Natural products 0.000 claims description 3
- 238000007689 inspection Methods 0.000 claims description 3
- 238000012545 processing Methods 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 206010010904 Convulsion Diseases 0.000 claims description 2
- 230000036461 convulsion Effects 0.000 claims description 2
- 239000002917 insecticide Substances 0.000 claims description 2
- 238000012856 packing Methods 0.000 claims description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 abstract description 29
- 239000008280 blood Substances 0.000 abstract description 29
- 230000000694 effects Effects 0.000 abstract description 13
- 238000012360 testing method Methods 0.000 abstract description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 5
- 238000005516 engineering process Methods 0.000 abstract description 3
- 210000000952 spleen Anatomy 0.000 abstract description 3
- 230000001225 therapeutic effect Effects 0.000 abstract description 3
- 231100000957 no side effect Toxicity 0.000 abstract description 2
- WTPPRJKFRFIQKT-UHFFFAOYSA-N 1,6-dimethyl-8,9-dihydronaphtho[1,2-g][1]benzofuran-10,11-dione;1-methyl-6-methylidene-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-10,11-dione Chemical compound O=C1C(=O)C2=C3CCCC(=C)C3=CC=C2C2=C1C(C)=CO2.O=C1C(=O)C2=C3CCC=C(C)C3=CC=C2C2=C1C(C)=CO2 WTPPRJKFRFIQKT-UHFFFAOYSA-N 0.000 abstract 1
- 235000017300 Alisma plantago Nutrition 0.000 abstract 1
- 244000233890 Alisma plantago Species 0.000 abstract 1
- 235000009917 Crataegus X brevipes Nutrition 0.000 abstract 1
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 abstract 1
- 235000009685 Crataegus X maligna Nutrition 0.000 abstract 1
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 abstract 1
- 235000009486 Crataegus bullatus Nutrition 0.000 abstract 1
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 abstract 1
- 235000009682 Crataegus limnophila Nutrition 0.000 abstract 1
- 235000004423 Crataegus monogyna Nutrition 0.000 abstract 1
- 240000000171 Crataegus monogyna Species 0.000 abstract 1
- 235000002313 Crataegus paludosa Nutrition 0.000 abstract 1
- 235000009840 Crataegus x incaedua Nutrition 0.000 abstract 1
- 206010062717 Increased upper airway secretion Diseases 0.000 abstract 1
- 244000170916 Paeonia officinalis Species 0.000 abstract 1
- 235000006484 Paeonia officinalis Nutrition 0.000 abstract 1
- 208000007536 Thrombosis Diseases 0.000 abstract 1
- 208000026435 phlegm Diseases 0.000 abstract 1
- 244000132619 red sage Species 0.000 abstract 1
- 238000005728 strengthening Methods 0.000 abstract 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 229960002297 fenofibrate Drugs 0.000 description 5
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 206010008118 cerebral infarction Diseases 0.000 description 3
- 208000026106 cerebrovascular disease Diseases 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 210000003725 endotheliocyte Anatomy 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- RBNPOMFGQQGHHO-UHFFFAOYSA-N -2,3-Dihydroxypropanoic acid Natural products OCC(O)C(O)=O RBNPOMFGQQGHHO-UHFFFAOYSA-N 0.000 description 2
- IBGBGRVKPALMCQ-UHFFFAOYSA-N 3,4-dihydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1O IBGBGRVKPALMCQ-UHFFFAOYSA-N 0.000 description 2
- KXNYCALHDXGJSF-UHFFFAOYSA-N 4,8-dimethyl-8,9-dihydronaphtho[2,1-f][1]benzofuran-7,11-dione Chemical compound CC1=CC=CC2=C(C(C=3OCC(C=3C3=O)C)=O)C3=CC=C21 KXNYCALHDXGJSF-UHFFFAOYSA-N 0.000 description 2
- XYKZSUXWBGUGQV-UHFFFAOYSA-N 4,8-dimethylnaphtho[2,1-f][1]benzofuran-7,11-dione Chemical compound CC1=CC=CC2=C(C(C=3OC=C(C=3C3=O)C)=O)C3=CC=C21 XYKZSUXWBGUGQV-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- GVKKJJOMQCNPGB-JTQLQIEISA-N Cryptotanshinone Chemical compound O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1[C@@H](C)CO2 GVKKJJOMQCNPGB-JTQLQIEISA-N 0.000 description 2
- GVKKJJOMQCNPGB-UHFFFAOYSA-N Cryptotanshinone Natural products O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1C(C)CO2 GVKKJJOMQCNPGB-UHFFFAOYSA-N 0.000 description 2
- RBNPOMFGQQGHHO-UWTATZPHSA-N D-glyceric acid Chemical compound OC[C@@H](O)C(O)=O RBNPOMFGQQGHHO-UWTATZPHSA-N 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- FEFAIBOZOKSLJR-UHFFFAOYSA-N Miltirone Chemical compound C1CCC(C)(C)C=2C1=C1C(=O)C(=O)C(C(C)C)=CC1=CC=2 FEFAIBOZOKSLJR-UHFFFAOYSA-N 0.000 description 2
- UILPJVPSNHJFIK-UHFFFAOYSA-N Paeonol Chemical compound COC1=CC=C(C(C)=O)C(O)=C1 UILPJVPSNHJFIK-UHFFFAOYSA-N 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N Tanshinone I Chemical compound C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- YKRGDOXKVOZESV-UHFFFAOYSA-N paeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(CO)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-UHFFFAOYSA-N 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000001648 tannin Substances 0.000 description 2
- 235000018553 tannin Nutrition 0.000 description 2
- 229920001864 tannin Polymers 0.000 description 2
- KZJWDPNRJALLNS-VPUBHVLGSA-N (-)-beta-Sitosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1 KZJWDPNRJALLNS-VPUBHVLGSA-N 0.000 description 1
- CSVWWLUMXNHWSU-UHFFFAOYSA-N (22E)-(24xi)-24-ethyl-5alpha-cholest-22-en-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 CSVWWLUMXNHWSU-UHFFFAOYSA-N 0.000 description 1
- PAFLSMZLRSPALU-MRVPVSSYSA-N (2R)-3-(3,4-dihydroxyphenyl)lactic acid Chemical compound OC(=O)[C@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-MRVPVSSYSA-N 0.000 description 1
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- KLEXDBGYSOIREE-UHFFFAOYSA-N 24xi-n-propylcholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CCC)C(C)C)C1(C)CC2 KLEXDBGYSOIREE-UHFFFAOYSA-N 0.000 description 1
- 241000331777 Arisaema balansae Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241001279228 Campylotropis hirtella Species 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 description 1
- XUSYGBPHQBWGAD-PJSUUKDQSA-N Carnosol Chemical compound CC([C@@H]1C2)(C)CCC[C@@]11C(=O)O[C@@H]2C2=C1C(O)=C(O)C(C(C)C)=C2 XUSYGBPHQBWGAD-PJSUUKDQSA-N 0.000 description 1
- MMFRMKXYTWBMOM-UHFFFAOYSA-N Carnosol Natural products CCc1cc2C3CC4C(C)(C)CCCC4(C(=O)O3)c2c(O)c1O MMFRMKXYTWBMOM-UHFFFAOYSA-N 0.000 description 1
- 206010065559 Cerebral arteriosclerosis Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- PAFLSMZLRSPALU-QMMMGPOBSA-N Danshensu Natural products OC(=O)[C@@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-QMMMGPOBSA-N 0.000 description 1
- ARVGMISWLZPBCH-UHFFFAOYSA-N Dehydro-beta-sitosterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CC=C21 ARVGMISWLZPBCH-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 229920000715 Mucilage Polymers 0.000 description 1
- 241000612122 Myrsine Species 0.000 description 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
- 235000018992 Prunus glandulosa Nutrition 0.000 description 1
- 240000001619 Prunus glandulosa Species 0.000 description 1
- 235000013999 Prunus japonica Nutrition 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- PAFLSMZLRSPALU-UHFFFAOYSA-N Salvianic acid A Natural products OC(=O)C(O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-UHFFFAOYSA-N 0.000 description 1
- GMBQZIIUCVWOCD-WWASVFFGSA-N Sarsapogenine Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CC[C@H](O)C[C@H]4CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@H](C)CO1 GMBQZIIUCVWOCD-WWASVFFGSA-N 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- RTMWIZOXNKJHRE-UHFFFAOYSA-N Tigogenin Natural products CC1COC2CC(C)(OC12)C3CCC4C5CCC6CC(O)CCC6(C)C5CCC34C RTMWIZOXNKJHRE-UHFFFAOYSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 229930188824 alisol Natural products 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 235000004654 carnosol Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- MDZKJHQSJHYOHJ-UHFFFAOYSA-N crataegolic acid Natural products C1C(O)C(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MDZKJHQSJHYOHJ-UHFFFAOYSA-N 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 229960003765 fluvastatin Drugs 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229960003627 gemfibrozil Drugs 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 201000005851 intracranial arteriosclerosis Diseases 0.000 description 1
- YLTGFGDODHXMFB-UHFFFAOYSA-N isoacetovanillon Natural products COC1=CC=C(C(C)=O)C=C1O YLTGFGDODHXMFB-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- MDZKJHQSJHYOHJ-LLICELPBSA-N maslinic acid Chemical compound C1[C@@H](O)[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MDZKJHQSJHYOHJ-LLICELPBSA-N 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229940042126 oral powder Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- MLIBGOFSXXWRIY-UHFFFAOYSA-N paeonol Natural products COC1=CC=C(O)C(C(C)=O)=C1 MLIBGOFSXXWRIY-UHFFFAOYSA-N 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229960003371 protocatechualdehyde Drugs 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 150000004053 quinones Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 1
- 235000015500 sitosterol Nutrition 0.000 description 1
- 230000037321 sleepiness Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a medicinal composition for treating hyperlipemia and a preparing method thereof. The medicinal composition is a Chinese patent medicine which has the advantages of convenient taking, obvious effect, short course of treatment and no side effect. The present invention is formed by that 32% to 40% of red peony roots, 24% to 28% of hawthorn fruits, 18% to 20% of danshen roots and 18% to 20% of water plantains are selected according to weight percentage, weighted, pulverized and made into powder, and then the quality of the powder is test. The medicinal composition has the effect of strengthening the spleen to reduce phlegm, reducing blood fat, blood sugar and alcohol, dispersing blood clots, removing stagnation of qi and treating the hyperlipemia. The present invention adopts a dry cutting method in technology, and thus, therapeutic effect is raised.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition, particularly relating to a kind of is the powder and preparation method thereof of raw material treatment hyperlipidemia with the Chinese herbal medicine.
Technical background
" cardiovascular " is the river of the life of human body, but improve constantly, lack physical training along with people's living standard, dietary structure, make the cholesterol and other lipid that are deposited in the human body artery tube wall form plaque gradually, tube chamber narrows down, produce the obstruction of lumen of vessels, thereby cause people to suffer from cerebral arteriosclerosis, cerebral infarction, coronary heart disease etc.Over nearly 20 years, blood-fat regulating medicine is of a great variety, difference according to main therapeutical effect, roughly be divided into two big classes: to reduce the Statins that pushes away that blood T-CHOL and low density lipoprotein, LDL are main head, as simvastatin, pravastatin and fluvastatin etc. and triglyceride reducing is that main person is representative with the special class of shellfish, as fenofibrate and gemfibrozil etc., they are line medicines of control dyslipidemia, effect with high density lipoprotein increasing, but slightly poor to the curative effect of triglyceride reducing and high density lipoprotein increasing.Disclosed a kind of application number on June 16th, 2004 and be the patent of 02153536 " the pharmaceutical composition that contains fenofibrate, preparation method and its usage with potent lipidemia disease " on the Chinese patent communique, its adopts a kind of chemistry that contains fenofibrate by name:
2-(4-(4-chlorobenzene formacyl) phenoxy group)-2 Methylpropionic acid isopropyl ester) new pharmaceutical formulation and preparation method thereof, though said preparation can improve the bioavailability and the slow release fenofibrate of fenofibrate, the healing curative effect is long.
Summary of the invention
In order to overcome the deficiencies in the prior art, the invention provides that a kind of preparation technology is simple, instant effect, short treating period, few side effects based on Chinese herbal medicine, have blood lipid-reducing blood sugar-decreasing and fall a kind of powder for the treatment of hyperlipidemia of alcohol and preparation method thereof.
The object of the present invention is achieved like this: a kind of powder for the treatment of hyperlipidemia, form by Radix Paeoniae Rubra, Fructus Crataegi, Radix Salviae Miltiorrhizae, Rhizoma Alismatis, be: Radix Paeoniae Rubra 32%~40%, Fructus Crataegi 24%~28%, Radix Salviae Miltiorrhizae 18%~20%, Rhizoma Alismatis 18%~20% according to each drug component of percentage by weight.The invention still further relates to the method for this drug powder of preparation, this method is that the several steps according to following order carries out:
1., selection: it is local wild and remove palpus that Radix Paeoniae Rubra is selected from the Inner Mongol
The red Radix Paeoniae of drying in the shade in the top; Fructus Crataegi is selected the Liao Dynasty, black, lucky for use
The wild fruit after frost dries in the shade sees in three provinces; Radix Salviae Miltiorrhizae is selected the river for use
The north Radix Salviae Miltiorrhizae also removes and must dry in the shade on the top; Rhizoma Alismatis is selected for use
The locality, Sichuan process yellow Rhizoma Alismatis.
Radix Paeoniae Rubra preparation: remove impurity, separately size, clean, run through 4 little
The time, this product is cut to circular section, diameter 0.5~
3cm, thick is 0.3~0.5cm sheet, supersound process
20 minutes, cool.
Fructus Crataegi preparation: the nuclear of removing impurity and coming off.
Radix Salviae Miltiorrhizae preparation: remove impurity and residual convulsion, clean, run through, cut thick
Sheet, drying.
Rhizoma Alismatis preparation: remove impurity, soak slightly, run through, cut sheet, do
Dry.Rhizoma Alismatis (processeded with salt) is by getting the Rhizoma Alismatis sheet, according to salt
The water method of processing is fried and is done.
1., weighing: each Chinese crude drug carries out weighing according to above-mentioned percentage by weight.
2., pulverize: the medical material after the weighing is done pressure method with Insecticide sprayer, pulverizes,
Cross 80 mesh sieves, system is loose behind the mixing.
3., packing: after diffusing the making, must within 3~5 hours, be sealed to bag, press
Adorn bag according to the 4.5g/ bag.
4., quality inspection: the test product powder for being prepared into has according to " state-promulgated pharmacopoeia "
Close aquametry and powder amount difference standard and measure,
After meeting the requirements, outbound.
Radix Paeoniae Rubra: the peoniflorin (C that this product contains
23H
28O
11) must not be less than 0.8%,
Most preferred peoniflorin (C
23H
28O
11) must not be less than 1.5%.
Fructus Crataegi: the organic acid of this product is with citric acid (C
6H
8O
7) must not be less than 5%,
Its preferred version is for containing organic acid with citric acid (C
6H
8O
7) must not
Be less than 4%.
Radix Salviae Miltiorrhizae: this product contains Tanshinone I I
A(C
19H
18O
3) must not be less than 0.2%.
Rhizoma Alismatis: the total ash of this product must not surpass 5%, acid-insoluble ash
Must not surpass 0.5%.
Theory of Chinese medical science of the present invention is according to being:
Radix Paeoniae Rubra: have another name called wooden Radix Paeoniae, red Radix Paeoniae, Radix clerodendri bungei, the main product Inner Mongol, Hebei, Liaoning, Heilungkiang, Jilin.Hardship is slightly cold, and goes into liver, spleen channel; Clearing away heat and cooling blood, blood circulation promoting and blood stasis dispelling.The Radix Paeoniae root contains paeoniflorin paeonol, paeoniflorin, benzoic acid, tannin, resin, volatile oil, cupreol, triterpenes etc., stomach, intestinal and uterine smooth muscle there is spasmolysis, and effects such as analgesia, calmness, analgesic, antiinflammatory, antiulcer are arranged, coronary flow is increased.
Fructus Crataegi: have another name called Chinese bush cherry, red fruit, ground such as main product Shandong, Hebei, Henan, Liaoning, Jiangsu.Sour, sweet, tepor are gone into spleen, stomach, Liver Channel.Have promoting digestion and removing stagnation, dissipating blood stasis.Contain citric acid, malic acid, Crataegolic acid, tannin, Saponin, fructose, vitamin C, protein and fat etc. in the Crataegi cuneatae fruit.
Radix Salviae Miltiorrhizae: have another name called Radix Salviae Miltiorrhizae, fry Radix Salviae Miltiorrhizae, Arisaema balansae Engl., Herba Wedeliae Wallichii root, Radix Campylotropis Hirtella (Herba Myrsines Africanae), ground such as main product Hebei, Anhui, Jiangsu, Sichuan.Bitter, cool, go into the heart, Liver Channel.Having blood circulation promoting and blood stasis dispelling, removing heat from blood eliminating carbuncle, relieving restlessness calms the nerves.This product contains crystallinity furo phenanthrenequione class pigment, and main is TANSHINONES 1A, IIB, cryptotanshinone, and the quinones pigment that dihydroisotanshinone I and multiple content are less is as the hydroxyl TANSHINONES; Iso tanshinone I, II, different cryptotanshinone, miltirone etc.; Other contains danshensu, carnosol, phenols branches such as protocatechualdehyde.In addition, contain vitamin E, B one sitosterol, steroid derivative tigogenin etc.Radix Salviae Miltiorrhizae is by blood fat reducing and antioxidation; prevent the plasma lipoprotein oxidation, alleviate the ultrastructure that endotheliocyte is protected in its damage to the arteries endotheliocyte; keep the normal function of the permeability of inner membrance and endotheliocyte secretion PCI, thereby alleviate the pathological changes of AS.
Rhizoma Alismatis: have another name called watery diarrhea and rush down, awns Yu, day bald, main product Fujian, Sichuan, Jiangxi.
Sweet, cold, go into kidney, urinary bladder channel, diuretic, eliminating dampness by diuresis, expel the heat-evil.This product contains triterpeness such as alisol and acetic acid alcohol thereof etc., has diuresis, lipotropy.
It is authentic medicinal herbs that Radix Paeoniae Rubra is selected the Radix Paeoniae Rubra of Inner Mongol for use; It is best medical material that Fructus Crataegi is selected the wild red fruit of Liaoning, Heilungkiang, Jilin San Sheng for use; It is top grade that Radix Salviae Miltiorrhizae is selected the Radix Salviae Miltiorrhizae in Hebei for use; It is good medicine that Rhizoma Alismatis is selected the Rhizoma Alismatis in Sichuan for use.Utilize Radix Paeoniae Rubra and Fructus Crataegi the coronary blood flow increasing function, utilize the function of blood sugar reduction of Radix Salviae Miltiorrhizae and Rhizoma Alismatis, four kinds of medicines are prepared and are reached blood lipid-reducing blood sugar-decreasing jointly and fall alcohol, cut the silt tissue regeneration promoting, the effect of treatment high fat of blood.
The present invention adopts name of product " blood fat treasured " powder, be because: the blood mucilage stagnates, fat polyalcohols collection, sugared high stasis of blood resistance.With " soup swings it " obviously dosage form not to its disease; Slow excessively with the ball pellet; And the cream Ji is easily mended; Only powder can loose, and its blood is sticking, its slurry that looses is stagnant, its fat that looses is poly-, its alcohol that looses collects, looses, and its sugar falls in its stasis of blood resistance, is the dosage form of suiting the medicine to the illness.
Compared with the prior art, the present invention is simple, the taking convenience of preparation technology not only, and instant effect energy expelling pathogenic factors from muscles expelling pathogenic factors from the exterior, and short treating period, economy have no side effect.
The specific embodiment
Below in conjunction with embodiment the present invention is further detailed.
Embodiment 1
At first the weight percent content according to pharmaceutical composition takes by weighing Radix Paeoniae Rubra 11.5g, Fructus Crataegi 7.5g, Radix Salviae Miltiorrhizae 5.5g, Rhizoma Alismatis 5.5g respectively, and with must removing on the top of Radix Paeoniae Rubra and Radix Salviae Miltiorrhizae, it is standby to dry in the shade; Fructus Crataegi selects for use frost to dry in the shade, and Rhizoma Alismatis is selected for use and processs yellow and be used as medicine.After after the weighing medical material being pulverized, crossed 80 mesh sieves, mixing, system is loose; Must within 3~5 hours, be sealed to bag after system is loose, adorn bag, after the assay was approved, outbound according to the 4.5g/ bag.
Embodiment 2
At first the weight percent content according to pharmaceutical composition takes by weighing Radix Paeoniae Rubra 40g, Fructus Crataegi 24g, Radix Salviae Miltiorrhizae 18g, Rhizoma Alismatis 18g respectively, and with must removing on the top of Radix Paeoniae Rubra and Radix Salviae Miltiorrhizae, it is standby to dry in the shade; Fructus Crataegi selects for use frost to dry in the shade, and Rhizoma Alismatis is selected for use and processs yellow and be used as medicine.After after the weighing medical material being pulverized, crossed 80 mesh sieves, mixing, system is loose; Must within 3~5 hours, be sealed to bag after system is loose, adorn bag, after the assay was approved, outbound according to the 4.5g/ bag.
Embodiment 3
At first the weight percent content according to pharmaceutical composition takes by weighing Radix Paeoniae Rubra 32g, Fructus Crataegi 28g, Radix Salviae Miltiorrhizae 20g, Rhizoma Alismatis 20g respectively, and with must removing on the top of Radix Paeoniae Rubra and Radix Salviae Miltiorrhizae, it is standby to dry in the shade; Fructus Crataegi selects for use frost to dry in the shade, and Rhizoma Alismatis is selected for use and processs yellow and be used as medicine.After after the weighing medical material being pulverized, crossed 80 mesh sieves, mixing, system is loose; Must within 3~5 hours, be sealed to bag after system is loose, adorn bag, after the assay was approved, outbound according to the 4.5g/ bag.
From nineteen ninety, the present invention adopts name of product " blood fat treasured " that 3126 routine patients are treated, and by clinical trial certificate, total effective rate is 98%, and clinical brief summary is as follows:
1., clinical data: treatment hyperlipidemia 3126 examples, male's 1612 examples, woman
Property 1514 examples; The oldest 72 years old, minimum 14 years old;
90 days the longest courses of treatment, be 29 days the course of treatment the shortest.
2., treatment foundation: hypercholesterolemia, high triglyceride.
3., Therapeutic Method: oral powder, every day 3 times, 4.5g~9g/ time 90 days was
A course of treatment.
4., best medicine time: 9~10 o'clock, 15~16 o'clock, 21~22 o'clock.
5., therapeutic outcome: hypercholesterolemia 2106 examples, cure 2098 examples; High glycerol three
Fat 1020 examples are cured 1011 examples, and cure rate is 99.5%.
6., the treatment standard: recovery from illness, clinical symptom disappearance after the course of treatment, not repeatedly, no
Bounce-back; Invalid, do not see change, it is little for effect.
7., total effective rate: 99.8%, do not see untoward reaction.
In the following table, 108 examples are adopted counter point, display result:
Group name | Case | Cholesterol meansigma methods mmol-% | Glyceric acid fat meansigma methods mmol-% | ||
Before | After | Before | After | ||
Matched group | 36 | 7.5±1.8 | 5.6±1.4 | 2.6±1.1 | 1.8±0.8 |
Test group | 72 | 8.0±2.3 | 4.5±1.2 | 3.2±1.0 | 1.0±0.8 |
As can be seen from the table: the present invention not only has cleaning action but also can fundamentally eliminate source of disease formed cholesterol, glyceric acid fat in the blood vessel.
Case 1
Cure the most young patient
Patient: Cao Liang, man, 14 years old, Jianshe Road, Qiqihaer City primary school student.On October 29th, 97 went to a doctor to Harbin Tiefeng District institute of traditional Chinese medicine, suffered from the long disease of sleeping, and five, six classes of will sleeping on class every day are also snored.Through examination blood, there is four indices to exceed normal value, be diagnosed as hyperlipidemia.Take " blood fat treasured " of the present invention after 90 days, in further consultation on January 30 in 98 year, the whole indexs of result of laboratory test were normal; Stay up on class at present, achievement is also progressive.
Case 2
Cure the longest, the oldest patient of curative effect
Patient: Zhang Leye, man, present 72 years old, the supervisory veteran cadre of place of Harbin Railway Bureau finance.Came institute of traditional Chinese medicine to go to a doctor on March 12nd, 94, the numerical value of the examining report of submitting to over 62 years old Zhang Leye had 12 normal reference values of ratio to exceed about one times at that time.Take " blood fat treasured " further consultation after 90 days, these 12 indexs of testing result are all normal.At present, the every index of this person is normal, takes this medicine for a long time, and does the detection of a hemorheology every hospital over 5 years.
Case 3
Cure the shortest patient of curative effect
Patient: open the sea, man, Qiqihar Vehicle Factory materialman.In March, 97, hospital admission suffered from the " deep sound sleep " disease, surveyed hemorheology, and blood viscosity height, erythrocyte sedimentation rate are fast as a result for they.Take " blood fat treasured " after 2 weeks, do not have sleepiness daytime, show that through the further consultation test result every index is normal, do not have repeatedly.
Case 4
Cure the patient who suffers from hyperlipidemia and suffer from cerebral infarction sequela
Patient: Song Shaoqiu, man, 48 years old, the defeated section of neat Railway transportation driver.Suffered from he of 2 years apoplexy at that time on February 7th, 98, the whole right part of health can not be arranged, tongue is stretched and do not exported, do not have language, difficulty in defecation, blood pressure 160/100, is carried on the back by wife and goes to a doctor.Hemorheology has 8 index superelevation after testing, is diagnosed as the cerebral infarction sequela of hyperlipidemia, begins to take " blood fat treasured " of the present invention 90 bag and logical craniums.After one course of treatment, further consultation, the TFL value when removing first visit normally, remaining 7 index just all has decline, continues to take former medicine.Through 3 courses of treatment, the patient can normal dialog, and index is normal, and right upper extremity is movable normal, right lower extremity muscle micro, and action can not put in place fully.Continue to take logical cranium and stretched muscle diffusing 3 months, on March 24th, 99, its right lower extremity withers to stretch out, and so far double is fully recovered freely.
Case 5
Cure the patient who suffers from blood fat type heart chest-rheumatism
Patient: Wang Guiqin, woman, 57 years old, Qiqihaer City's railway south office dormitory.Came institute of traditional Chinese medicine to go to a doctor on February 28th, 98, she suffered from heart chest-rheumatism at that time, pulse closely stops 1 time for per 12 times.Take the present invention's " blood fat treasured " and heart and brain I# after one month, it is much better that breast is felt, its arteries and veins nearly about 35 stops once, continues to take this medicine.After 3 months, abnormal four indices of hemorheology is all normal, and ultrasound wave is pointed out intracardiac structure no abnormality seen, recovers normal.
Claims (3)
1, a kind of powder for the treatment of hyperlipidemia is characterized in that being made up of following components in weight percentage:
Radix Paeoniae Rubra 32%~40%,
Fructus Crataegi 24%~28%,
Radix Salviae Miltiorrhizae 18%~20%,
Rhizoma Alismatis 18%~20%.
2, a kind of preparation method for the treatment of the powder of hyperlipidemia according to claim 1 is characterized in that this method prepares according to the following step:
1., selection: it is local wild and remove the red Radix Paeoniae of must the top drying in the shade that Radix Paeoniae Rubra is selected from the Inner Mongol; Fructus Crataegi selects for use the Liao Dynasty, black, Ji San to economize the wild fruit that sees after frost dries in the shade; Radix Salviae Miltiorrhizae is selected the Hebei Radix Salviae Miltiorrhizae for use and is removed and must dry in the shade on the top; Rhizoma Alismatis is selected the yellow Rhizoma Alismatis of processing of locality, Sichuan for use;
The Radix Paeoniae Rubra preparation: remove impurity, separate size, clean, run through 4 hours, this product is cut to circular section, diameter 0.5~3cm, thick is 0.3~0.5cm sheet, supersound process 20 minutes, cools;
Fructus Crataegi preparation: the nuclear of removing impurity and coming off;
Radix Salviae Miltiorrhizae preparation: remove impurity and residual convulsion, clean, run through, cut sheet, drying;
Rhizoma Alismatis preparation: remove impurity, soak slightly, run through, cut sheet, drying; Rhizoma Alismatis (processeded with salt) is by getting the Rhizoma Alismatis sheet, frying according to the saline method of processing and do;
2., weighing: each Chinese crude drug carries out weighing according to above-mentioned percentage by weight;
3., pulverize: the medical material after the weighing, do pressure method with Insecticide sprayer and pulverize, cross 80 mesh sieves, system is loose behind the mixing;
4., packing: after diffusing the making, must within 3~5 hours, be sealed to bag, adorn bag according to the 4.5g/ bag;
5., quality inspection:, carry out about aquametry and powder amount difference standard according to " state-promulgated pharmacopoeia " for the powder that is prepared into
Measure, after meeting the requirements, outbound;
Radix Paeoniae Rubra: the peoniflorin that this product contains must not be less than 0.8%;
Fructus Crataegi: the organic acid of this product must not be less than 5% with citric acid;
Radix Salviae Miltiorrhizae: this product contains TANSHINONES must not be less than 0.2%;
Rhizoma Alismatis: the total ash of this product is no more than 5%, and acid-insoluble ash must not surpass 0.5%.
3, the preparation method of the powder of treatment hyperlipidemia according to claim 2 is characterized in that: the peoniflorin amount of Radix Paeoniae Rubra is no less than 1.5% in the quality inspection, and organic acid is no less than 4% with citric acid in the Fructus Crataegi.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB200510007322XA CN1313126C (en) | 2005-02-06 | 2005-02-06 | Medicine composition for treating hyperlipemia and its preparing method |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB200510007322XA CN1313126C (en) | 2005-02-06 | 2005-02-06 | Medicine composition for treating hyperlipemia and its preparing method |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1682800A CN1682800A (en) | 2005-10-19 |
CN1313126C true CN1313126C (en) | 2007-05-02 |
Family
ID=35262419
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB200510007322XA Expired - Fee Related CN1313126C (en) | 2005-02-06 | 2005-02-06 | Medicine composition for treating hyperlipemia and its preparing method |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1313126C (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1985909B (en) * | 2007-01-08 | 2010-06-16 | 江苏济川制药有限公司 | Medicine for hyperlipemia and its production process |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1232693A (en) * | 1999-03-09 | 1999-10-27 | 李胤良 | Health beverage for preventing and curing hypertension and hyperlipemia |
CN1329893A (en) * | 2000-06-16 | 2002-01-09 | 杨传平 | Chinese medicine for decreasing fat and lossing weight and preparation method thereof |
-
2005
- 2005-02-06 CN CNB200510007322XA patent/CN1313126C/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1232693A (en) * | 1999-03-09 | 1999-10-27 | 李胤良 | Health beverage for preventing and curing hypertension and hyperlipemia |
CN1329893A (en) * | 2000-06-16 | 2002-01-09 | 杨传平 | Chinese medicine for decreasing fat and lossing weight and preparation method thereof |
Non-Patent Citations (3)
Title |
---|
中医治疗高血脂症 陈永久,民族医药报 2003 * |
他汀类药物在国内外发展状况 于丽珊,中国中医药报 2002 * |
他汀类药物在国内外发展状况 于丽珊,中国中医药报 2002;中医治疗高血脂症 陈永久,民族医药报 2003 * |
Also Published As
Publication number | Publication date |
---|---|
CN1682800A (en) | 2005-10-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1051237C (en) | Meicinal prepn. "Kexianling" for curing epilepsy | |
CN104013681A (en) | Pharmaceutical composition for treating kidney stone | |
CN1233251C (en) | Tea capable of preventing and curing hypertension | |
CN1840128A (en) | Medicine for treating cardiovascular disease | |
CN103301267A (en) | Traditional Chinese medicine composition for treating hypertension and/or atherosclerosis and application thereof | |
CN101053619A (en) | Medicine for treating pulmonary fibrosis | |
CN103977390B (en) | A kind of preparation method and its usage of ginger onion medicated wine composition | |
CN1313126C (en) | Medicine composition for treating hyperlipemia and its preparing method | |
CN103028071B (en) | Traditional Chinese medicine composition for treating diarrhea-dominant irritable bowel syndrome and preparation method of traditional Chinese medicine composition | |
CN105456689A (en) | Traditional Chinese medicine composition for treating diabetes as well as preparation method and application of traditional Chinese medicine composition | |
CN1857607A (en) | Chinese medicine preparation for treating cardiac and cerebral vascular diseases and its preparing process | |
CN1857605A (en) | Medicine for treating chronic alcoholic hepatopathy and its preparing method | |
CN1182864C (en) | A kind of medicine for treating vascular dementia and its preparation method | |
CN1127344C (en) | Oral pill for curing diabetes and its complication | |
CN1679892A (en) | Oral liquid for treating cancer and preparation thereof | |
CN1272047C (en) | Medicine for invigorating liver and kidney to treat dryness of large intestine and constipation | |
CN110522798A (en) | A kind of compound preparation and preparation method thereof curing mainly coronary heart disease | |
CN103301372B (en) | Preparation method of umbilicus dressing agent for treating post-operation prostate stress urinary incontinence | |
CN112089783B (en) | Application of traditional Chinese medicine composition in the preparation of medicine for preventing or/and treating obesity | |
CN114767804B (en) | Acupoint application for treating bronchial asthma and preparation method thereof | |
CN1299718C (en) | Medicine for treating cardio-cerebral vascular disease and its preparing method | |
CN1299752C (en) | Traditional Chinese medicine capsule for treating urinary calculus and its prepn. method | |
CN1279965C (en) | Traditional Chinese medicine preparation for treating cranial vascular diseases, its preparation method and application | |
CN1712055A (en) | Chinese medicinal preparation (litholytic capsule) for treating urinific calculus | |
CN1686194A (en) | Medicine for treating hemicrania and its preparation method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070502 Termination date: 20100206 |